In addition, MSLN has become a popular target for targeted anti-tumor therapy due to its high differential expression, including monoclonal antibodies, antibody drug combinations (ADCs), radioimmunotherapy (RIT), CAR-T cell immunotherapy for mesothelioma, etc. (16–18). This evidence concerns the gene MSLN and neoplasm.